{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:14:17Z","timestamp":1789604057634,"version":"build-2803163510"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2006,9,27]],"date-time":"2006-09-27T00:00:00Z","timestamp":1159315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,9,27]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Vaccinia virus (VV) has been tested as oncolytic virus against malignant melanoma in clinical trials for more than 40\u2003years. Until now, mainly strains comparable to viral strains used for smallpox vaccination have been probed for anti-tumoral therapy. We have shown recently that the wild-type strain Western Reserve (WR) can interfere with crucial functions of monocyte-derived dendritic cells (DCs). Our aim was to examine whether viral immune evasion mechanisms might be responsible for the ineffectiveness of WR-based vaccination strategies and whether the highly attenuated strain modified virus Ankara (MVA) differs from WR with respect to its possible immunostimulatory capacity after intratumoral injection. Using in vitro experiments, we compared the effect of both strains on melanoma cells and on local bystander DCs. We found that both VV-strains infected melanoma cells efficiently and caused disintegration of the actin cytoskeleton, as shown by fluorescence microscopy. In addition, both VV-strains caused apoptotic cell death in melanoma cells after infection. In contrast to MVA, WR underwent a complete viral replication cycle in melanoma cells. Bystander DCs were consecutively infected by newly generated WR virions and lost their capacity to induce allogeneic T cell proliferation. DCs in contact with MVA-infected melanoma cells retained their capacity to induce T cell proliferation. Immature DCs were capable of phagocytosing MVA-infected melanoma cells. Priming of autologous CD8+ T cells by DCs that had phagocytosed MVA-infected, MelanA positive melanoma cells resulted in the induction of T cell clones specifically reactive against the model antigen MelanA as shown by enzyme-linked immunospot (ELISPOT) analysis. We conclude that the clinical trials with oncolytic wild-type VV failed probably because of suppression of bystander DCs and consecutive suppression of T cell-mediated anti-melanoma immunity. The attenuated VV-strain MVA facilitates the generation of tumour associated antigen (TAA)-specific T cell response as it is oncolytic for melanoma cells, but non-toxic for DC, and should be a promising candidate for intralesional metastatic melanoma therapy.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2006.03177.x","type":"journal-article","created":{"date-parts":[[2006,9,27]],"date-time":"2006-09-27T09:42:55Z","timestamp":1159350175000},"page":"344-353","source":"Crossref","is-referenced-by-count":50,"title":["The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity"],"prefix":"10.1093","volume":"146","author":[{"given":"S","family":"Greiner","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Y","family":"Humrich","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Erlangen, Erlangen, Germany"},{"name":"Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Thuman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Sauter","sequence":"additional","affiliation":[{"name":"Hautzentrum Sellspeicher, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Schuler","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Jenne","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Erlangen, Erlangen, Germany"},{"name":"Hautzentrum Sellspeicher, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,9,27]]},"reference":[{"key":"2022010503194618400_b1","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/1523-1747.ep12292705","article-title":"T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas","volume":"108","author":"Lowes","year":"1997","journal-title":"J Invest Dermatol"},{"key":"2022010503194618400_b2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1034\/j.1600-065X.2002.18806.x","article-title":"Tumor-specific shared antigenic peptides recognized by human T cells","volume":"188","author":"Van","year":"2002","journal-title":"Immunol Rev"},{"key":"2022010503194618400_b3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/1097-0142(197602)37:2<735::AID-CNCR2820370221>3.0.CO;2-Z","article-title":"A clinical histologic, and immunologic study of a case of metastatic malignant melanoma undergoing spontaneous remission","volume":"37","author":"Bodurtha","year":"1976","journal-title":"Cancer"},{"key":"2022010503194618400_b4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/00000658-198201001-00007","article-title":"A multivariate analysis of prognostic factors for melanoma patients with lesions greater than or equal to 3.65 mm in thickness. The importance of revealing alternative Cox models","volume":"195","author":"Day","year":"1982","journal-title":"Ann Surg"},{"key":"2022010503194618400_b5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.immunol.24.021605.090733","article-title":"Human T cell responses against melanoma","volume":"24","author":"Boon","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"2022010503194618400_b6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1610-0387.2003.02014.x","article-title":"Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease","volume":"1","author":"Voit","year":"2003","journal-title":"J Dtsch Dermatol Ges"},{"key":"2022010503194618400_b7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1084\/jem.126.1.93","article-title":"Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus","volume":"126","author":"Lindenmann","year":"1967","journal-title":"J Exp Med"},{"key":"2022010503194618400_b8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0960-7404(01)00020-2","article-title":"Overview analysis of adjuvant therapies for melanoma\u2003\u2212\u2003a special reference to results from vaccinia melanoma oncolysate adjuvant therapy trials","volume":"10","author":"Kim","year":"2001","journal-title":"Surg Oncol"},{"key":"2022010503194618400_b9","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1200\/JCO.2002.12.094","article-title":"Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial","volume":"20","author":"Hersey","year":"2002","journal-title":"J Clin Oncol"},{"key":"2022010503194618400_b10","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/archderm.1974.01630050014003","article-title":"Immunotherapy of malignant melanoma with vaccinia virus","volume":"109","author":"Roenigk","year":"1974","journal-title":"Arch Dermatol"},{"key":"2022010503194618400_b11","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.cgt.7700538","article-title":"Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors","volume":"9","author":"Mastrangelo","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"2022010503194618400_b12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00262-004-0616-7","article-title":"A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)","volume":"54","author":"Meyer","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"2022010503194618400_b13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1089\/10430340252809856","article-title":"Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and co-stimulatory molecules in vivo","volume":"13","author":"Oertli","year":"2002","journal-title":"Hum Gene Ther"},{"key":"2022010503194618400_b14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S1471-4906(00)01813-5","article-title":"Viral vectors for dendritic cell-based immunotherapy","volume":"22","author":"Jenne","year":"2001","journal-title":"Trends Immunol"},{"key":"2022010503194618400_b15","first-page":"241","article-title":"Viral vectors for dendritic cell-based immunotherapy","volume":"276","author":"Humrich","year":"2003","journal-title":"Curr Top Microbiol Immunol"},{"key":"2022010503194618400_b16","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/sj.gt.3301287","article-title":"Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function","volume":"7","author":"Jenne","year":"2000","journal-title":"Gene Ther"},{"key":"2022010503194618400_b17","first-page":"4955","article-title":"Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo","volume":"59","author":"Drexler","year":"1999","journal-title":"Cancer Res"},{"key":"2022010503194618400_b18","first-page":"4446","article-title":"Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis","volume":"60","author":"Jenne","year":"2000","journal-title":"Cancer Res"},{"key":"2022010503194618400_b19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1471-4906(01)01860-9","article-title":"Dendritic cells resurrect antigens from dead cells","volume":"22","author":"Larsson","year":"2001","journal-title":"Trends Immunol"},{"key":"2022010503194618400_b20","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1073\/pnas.89.22.10847","article-title":"Nonreplicating vaccinia vector efficiently expresses recombinant genes","volume":"89","author":"Sutter","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022010503194618400_b21","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.4049\/jimmunol.160.3.1139","article-title":"Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1- biasing cytokines IL-12 and IFN-alpha","volume":"160","author":"Tuting","year":"1998","journal-title":"J Immunol"},{"key":"2022010503194618400_b22","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1002\/eji.1830271209","article-title":"Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions","volume":"27","author":"Jonuleit","year":"1997","journal-title":"Eur J Immunol"},{"key":"2022010503194618400_b23","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1084\/jem.20012100","article-title":"Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells","volume":"195","author":"Schuler-Thurner","year":"2002","journal-title":"J Exp Med"},{"key":"2022010503194618400_b24","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.4049\/jimmunol.160.4.1750","article-title":"Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A\/MART-1 immunodominant peptide analogues","volume":"160","author":"Valmori","year":"1998","journal-title":"J Immunol"},{"key":"2022010503194618400_b25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0955-0674(00)00180-0","article-title":"Viral transport and the cytoskeleton","volume":"13","author":"Ploubidou","year":"2001","journal-title":"Curr Opin Cell Biol"},{"key":"2022010503194618400_b26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1006\/viro.1998.9123","article-title":"The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses","volume":"244","author":"Antoine","year":"1998","journal-title":"Virology"},{"key":"2022010503194618400_b27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-1759(03)00102-9","article-title":"Antigen loading of dendritic cells with whole tumor cell preparations","volume":"277","author":"Thumann","year":"2003","journal-title":"J Immunol Meth"},{"key":"2022010503194618400_b28","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0140-6736(70)91790-3","article-title":"Viruses in the treatment of cancer","volume":"1","author":"Webb","year":"1970","journal-title":"Lancet"},{"key":"2022010503194618400_b29","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2217\/14796694.1.6.763","article-title":"Elucidation of the molecular mechanism underlying tumor-selective replication of the oncolytic adenovirus mutant ONYX-015","volume":"1","author":"Ries","year":"2005","journal-title":"Fut Oncol"},{"key":"2022010503194618400_b30","doi-asserted-by":"crossref","first-page":"7802","DOI":"10.1038\/sj.onc.1209037","article-title":"Oncolytic viral therapies\u2003\u2212\u2003the clinical experience","volume":"24","author":"Aghi","year":"2005","journal-title":"Oncogene"},{"key":"2022010503194618400_b31","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1046\/j.1523-1747.2002.00643.x","article-title":"Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study","volume":"119","author":"Pfahlberg","year":"2002","journal-title":"J Invest Dermatol"},{"key":"2022010503194618400_b32","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1055-3207(02)00025-X","article-title":"Viral oncolysis","volume":"11","author":"Donahue","year":"2002","journal-title":"Surg Oncol Clin N Am"},{"key":"2022010503194618400_b33","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1517\/14712598.4.8.1307","article-title":"Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus","volume":"4","author":"Thorne","year":"2004","journal-title":"Exp Opin Biol Ther"},{"key":"2022010503194618400_b34","first-page":"1632","article-title":"A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer","volume":"6","author":"Eder","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2022010503194618400_b35","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s002620000146","article-title":"Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule","volume":"49","author":"Horig","year":"2000","journal-title":"Cancer Immunol Immunother"},{"key":"2022010503194618400_b36","first-page":"2219","article-title":"Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas","volume":"6","author":"Von Mehren","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2022010503194618400_b37","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.4049\/jimmunol.164.8.4204","article-title":"Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3","volume":"164","author":"Yang","year":"2000","journal-title":"J Immunol"},{"key":"2022010503194618400_b38","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1242\/jcs.00622","article-title":"Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases","volume":"116","author":"Woodring","year":"2003","journal-title":"J Cell Sci"},{"key":"2022010503194618400_b39","first-page":"277","article-title":"Proteolytic and non-proteolytic migration of tumour cells and leucocytes","volume-title":"Biochem Soc Symp","author":"Friedl","year":"2003"},{"key":"2022010503194618400_b40","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nrc1075","article-title":"Tumour-cell invasion and migration: diversity and escape mechanisms","volume":"3","author":"Friedl","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"2022010503194618400_b41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0092-8674(01)00448-2","article-title":"Dendritic cells as vectors for therapy","volume":"106","author":"Banchereau","year":"2001","journal-title":"Cell"},{"key":"2022010503194618400_b42","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1084\/jem.192.11.1535","article-title":"Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells","volume":"192","author":"Berard","year":"2000","journal-title":"J Exp Med"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2006.03177.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/146\/2\/344\/42063849\/j.1365-2249.2006.03177.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/146\/2\/344\/42063849\/j.1365-2249.2006.03177.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:09:13Z","timestamp":1683590953000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/146\/2\/344\/6458971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,27]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2006,9,27]]},"published-print":{"date-parts":[[2006,9,27]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2006.03177.x","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,11]]},"published":{"date-parts":[[2006,9,27]]}}}